SCYX-7158
 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C17H14BF4NO3 |
| Molar mass | 367.102 |
| 3D model (JSmol) | |
| |
| |
SCYX-7158 (AN-5568) is an antiprotozoal drug invented by Anacor Pharmaceuticals in 2009,[1][2] and now under development by the Drugs for Neglected Diseases Initiative for the treatment of African trypanosomiasis (Sleeping sickness). It is a structurally novel drug described as a benzoxaborole derivative, and is the first orally active drug treatment developed for sleeping sickness. Phase I human clinical trials were completed successfully in 2015, and it is now in Phase IIb/III trials being carried out in the Democratic Republic of the Congo, where most cases of sleeping sickness occur.[3]
See also
References
- ↑ Jacobs R, et al. Efficacy and Pharmacokinetics of SCYX-7158 (AN5568): a Novel and Potent Oxaborole-6-Carboxamide Selected as a Pre-Clinical Candidate for Once-Daily Oral Treatment for Stage 2 Human African Trypanosomiasis. (Conference Paper, 2009).
- ↑ Jacobs RT, Nare B, Wring SA, Orr MD, Chen D, Sligar JM, Jenks MX, Noe RA, Bowling TS, Mercer LT, Rewerts C, Gaukel E, Owens J, Parham R, Randolph R, Beaudet B, Bacchi CJ, Yarlett N, Plattner JJ, Freund Y, Ding C, Akama T, Zhang YK, Brun R, Kaiser M, Scandale I, Don R. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis. 2011 Jun;5(6):e1151. doi: 10.1371/journal.pntd.0001151. PMID 21738803
- ↑ DNDi announces successful completion of SCYX-7158 Phase I study for treatment of sleeping sickness. 9 September 2015
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.